The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Publications

Tsubata Y, Hamada A, Sutani A, Isobe T

Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.

Journal of cancer research and therapeutics. 2012;8(1):154-6

Onal C, Abali H, Koc Z, Kara S

Radiation recall pneumonitis caused by erlotinib after palliative definitive radiotherapy.

Onkologie. 2012;35(4):191-4

ter Heine R, van den Bosch RT, Schaefer-Prokop CM, Lankheet NA, Beijnen JH, Staaks GH, van der Westerlaken MM, Malingré MM, van den Brand JJ

Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.

Lung cancer (Amsterdam, Netherlands). 2012;75(3):391-7

Del Castillo Y, Espinosa P, Bodí F, Alcega R, Muñoz E, Rabassó C, Castander D

Interstitial lung disease associated to erlotinib treatment: a case report.

Cases journal. 2010;3:59

Taj A, Kanjwal S, Hammersley JR

New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung.

American journal of therapeutics. 2011;18(1):e19-21

Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, Hida T, Kawahara M, Katakami N, Takeda K, Yokoyama A, Noda K, Fukuoka M, Saijo N

Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008;3(12):1439-45